Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial.
Meininger V, Pradat PF, Corse A, Al-Sarraj S, Rix Brooks B, Caress JB, Cudkowicz M, Kolb SJ, Lange D, Leigh PN, Meyer T, Milleri S, Morrison KE, Orrell RW, Peters G, Rothstein JD, Shefner J, Lavrov A, Williams N, Overend P, Price J, Bates S, Bullman J, Krull D, Berges A, Abila B, Meno-Tetang G, Wurthner J. Meininger V, et al. Among authors: lavrov a. PLoS One. 2014 May 19;9(5):e97803. doi: 10.1371/journal.pone.0097803. eCollection 2014. PLoS One. 2014. PMID: 24841795 Free PMC article. Clinical Trial.
Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Meininger V, Genge A, van den Berg LH, Robberecht W, Ludolph A, Chio A, Kim SH, Leigh PN, Kiernan MC, Shefner JM, Desnuelle C, Morrison KE, Petri S, Boswell D, Temple J, Mohindra R, Davies M, Bullman J, Rees P, Lavrov A; NOG112264 Study Group. Meininger V, et al. Among authors: lavrov a. Lancet Neurol. 2017 Mar;16(3):208-216. doi: 10.1016/S1474-4422(16)30399-4. Epub 2017 Jan 28. Lancet Neurol. 2017. PMID: 28139349 Free article. Clinical Trial.
The use of biotelemetry to explore disease progression markers in amyotrophic lateral sclerosis.
Kelly M, Lavrov A, Garcia-Gancedo L, Parr J, Hart R, Chiwera T, Shaw CE, Al-Chalabi A, Marsden R, Turner MR, Talbot K. Kelly M, et al. Among authors: lavrov a. Amyotroph Lateral Scler Frontotemporal Degener. 2020 Nov;21(7-8):563-573. doi: 10.1080/21678421.2020.1773501. Epub 2020 Jun 23. Amyotroph Lateral Scler Frontotemporal Degener. 2020. PMID: 32573278 Free article.
Innovating Clinical Trials for Amyotrophic Lateral Sclerosis: Challenging the Established Order.
van Eijk RPA, Nikolakopoulos S, Roes KCB, Kendall L, Han SS, Lavrov A, Epstein N, Kliest T, de Jongh AD, Westeneng HJ, Al-Chalabi A, Van Damme P, Hardiman O, Shaw PJ, McDermott CJ, Eijkemans MJC, van den Berg LH. van Eijk RPA, et al. Among authors: lavrov a. Neurology. 2021 Sep 14;97(11):528-536. doi: 10.1212/WNL.0000000000012545. Epub 2021 Jul 27. Neurology. 2021. PMID: 34315786 Free PMC article.
Using the ALSFRS-R in multicentre clinical trials for amyotrophic lateral sclerosis: potential limitations in current standard operating procedures.
Bakers JNE, de Jongh AD, Bunte TM, Kendall L, Han SS, Epstein N, Lavrov A, Beelen A, Visser-Meily JMA, van den Berg LH, van Eijk RPA. Bakers JNE, et al. Among authors: lavrov a. Amyotroph Lateral Scler Frontotemporal Degener. 2022 Nov;23(7-8):500-507. doi: 10.1080/21678421.2021.2016838. Epub 2021 Dec 24. Amyotroph Lateral Scler Frontotemporal Degener. 2022. PMID: 34949141 Free article.
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial.
Mercuri E, Muntoni F, Baranello G, Masson R, Boespflug-Tanguy O, Bruno C, Corti S, Daron A, Deconinck N, Servais L, Straub V, Ouyang H, Chand D, Tauscher-Wisniewski S, Mendonca N, Lavrov A; STR1VE-EU study group. Mercuri E, et al. Among authors: lavrov a. Lancet Neurol. 2021 Oct;20(10):832-841. doi: 10.1016/S1474-4422(21)00251-9. Lancet Neurol. 2021. PMID: 34536405 Clinical Trial.
Onasemnogene abeparvovec preserves bulbar function in infants with presymptomatic spinal muscular atrophy: a post-hoc analysis of the SPR1NT trial.
Shell RD, McGrattan KE, Hurst-Davis R, Young SD, Baranello G, Lavrov A, O'Brien E, Wallach S, LaMarca N, Reyna SP, Darras BT. Shell RD, et al. Among authors: lavrov a. Neuromuscul Disord. 2023 Aug;33(8):670-676. doi: 10.1016/j.nmd.2023.06.005. Epub 2023 Jun 22. Neuromuscul Disord. 2023. PMID: 37455203 Free article.
174 results